Celanese Corporation
1601 West LBJ Freeway
Dallas, Texas 75234-6034
Corporate News Release
Celanese Signs Agreement to Sell Oxo Products and Derivatives Businesses to
Advent International
DALLAS,
Dec. 13, 2006 Celanese Corporation (NYSE: CE) today announced that it has
entered into an agreement to sell its oxo products and derivatives businesses, including European
Oxo GmbH (EOXO), a joint venture between Celanese AG and Degussa AG, to Advent International, a
global private equity firm, for the purchase price of EUR
480 million, which is approximately USD
$630 million at current exchange rates. This sale is consistent with Celaneses strategy to
optimize its portfolio and divest non-core businesses.
Celanese is committed to a hybrid business model with leading global businesses that are
integrated and focused around core strengths, said David Weidman, president and chief executive
officer. This sale allows us to continue our strategic execution to focus our portfolio and
position Celanese for strong, sustainable earnings growth and increased value.
The sale includes oxo and derivative businesses at Celaneses Oberhausen, Germany, and Bay
City, Texas, facilities; and portions of its Bishop, Texas, facility. EOXOs facilities within the
Oberhausen and Marl, Germany, plants are also included in the sale. As part of the transaction,
Celanese will transfer all of the EOXO business to Advent International, including Degussas 50
percent interest of the venture.
We are confident that customer supply will not be disrupted as we transition through this
process, Weidman said. In addition, we believe that this sale will allow Advent International to
focus and further strengthen these businesses in a manner consistent with customer interests.
Leveraging Advents industry sector knowledge, we will work with this acquired business
management team to integrate its activities and accelerate growth, said Ronald Ayles, principal,
Advent International.
The oxo derivative chemicals business of Celanese, which has approximately 1,100 employees,
earns revenues of approximately $700 million and has EBITDA margins of about 10 percent. EOXO,
which has approximately 200 employees, has non-consolidated revenues of approximately $700 million
and contributes $5 million to $10 million of equity earnings to Celanese annually. The transaction
is subject to customary closing conditions, including consent from senior secured lenders and
regulatory approvals.
The company will discuss this transaction in further detail at its previously scheduled
investor conference, Wednesday, Dec. 13, 2006, in New York, beginning at 8:30 a.m., hosted by David
Weidman. A live Web cast of the event can be accessed at
www.celanese.com
Contacts:
|
|
|
|
|
Investor Relations
|
|
Media U.S.
|
|
Media Europe
|
Mark Oberle
|
|
Jeremy Neuhart
|
|
Michael Kraft
|
Phone: +1 972 443 4464
|
|
Phone: +1 972 443 3750
|
|
Phone: +49 69 30514072
|
Telefax: +1 972 332 9373
|
|
Telefax: +1 972 443 8519
|
|
Telefax: +49 69 30536787
|
Email:
Mark.Oberle@celanese.com
|
|
Jeremy.Neuhart@celanese.com
|
|
Email:
M.Kraft@celanese.com
|
As a global leader in the chemicals industry, Celanese Corporation makes products essential to
everyday living. Our products, found in consumer and industrial applications, are manufactured in
North America, Europe and Asia. Net sales totaled $6.1 billion in 2005, with approximately 60%
generated outside of North America. Known for operational excellence and execution of its business
strategies, Celanese delivers value to customers around the globe with innovations and best-
in-class technologies. Based in Dallas, Texas, the company employs approximately 9,300 employees
worldwide. For more information on Celanese Corporation, please visit the companys website at
www.celanese.com
.
Forward-looking statements
(statements which are not historical facts) in this release are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties,
including those risks and uncertainties detailed in the Companys filings with the Securities and
Exchange Commission, copies of which are available from the Company.